Summary
Biogen Idec Inc. presented its 2012 annual report, highlighting strong revenue growth driven by its key products in multiple sclerosis (MS) and other therapeutic areas. AVONEX and TYSABRI showed continued sales increases, contributing significantly to the company's top line. The company also reported substantial investment in research and development, with a focus on advancing its pipeline, particularly for MS treatments like TECFIDERA, which was undergoing regulatory review. The report emphasizes Biogen Idec's commitment to innovation and its strategy to address unmet medical needs in challenging disease areas. Despite facing competitive pressures and evolving regulatory landscapes, the company maintained a solid financial position with robust cash reserves, supporting its ongoing development and commercialization efforts.
Financial Highlights
57 data pointsBeta
Financial Statements
Beta
| Revenue | $5.52B |
| Cost of Revenue | $545.49M |
| Gross Profit | $4.97B |
| R&D Expenses | $1.33B |
| SG&A Expenses | $1.28B |
| Operating Expenses | $3.71B |
| Operating Income | $1.86B |
| Interest Expense | $36.50M |
| Net Income | $1.38B |
| EPS (Basic) | $5.80 |
| EPS (Diluted) | $5.76 |
| Shares Outstanding (Basic) | 237.94M |
| Shares Outstanding (Diluted) | 239.74M |
Key Highlights
- 1Biogen Idec's primary revenue drivers, AVONEX and TYSABRI, demonstrated significant year-over-year revenue growth in 2012, indicating sustained market demand in the multiple sclerosis (MS) segment.
- 2The company reported substantial investment in research and development (R&D), with expenditures totaling $1,334.9 million in 2012, underscoring its commitment to pipeline advancement.
- 3TECFIDERA, an oral MS treatment candidate, was highlighted as a key late-stage program with marketing applications submitted to regulatory authorities, representing a significant potential growth driver.
- 4TYSABRI, despite its safety warnings (PML risk), showed continued sales growth, demonstrating its established efficacy and the company's risk management strategies.
- 5The company's collaboration with Genentech on RITUXAN for non-Hodgkin's lymphoma and rheumatoid arthritis also contributed positively to revenue, with a notable increase in the company's share of pre-tax co-promotion profits.
- 6Biogen Idec maintained a strong financial position, with cash, cash equivalents, and marketable securities totaling $3,742.4 million as of December 31, 2012, providing liquidity for ongoing operations and future investments.
- 7The company actively repurchased shares of its common stock, demonstrating a commitment to returning value to shareholders, with approximately 7.8 million shares repurchased in 2012.
Frequently Asked Questions
Biogen Idec's primary revenue-generating products are AVONEX and TYSABRI, both used for the treatment of multiple sclerosis (MS). RITUXAN, a collaboration with Genentech, also significantly contributes to revenue, treating non-Hodgkin's lymphoma and rheumatoid arthritis.
Biogen Idec is heavily invested in R&D, with a significant focus on neurological diseases, particularly MS. Key pipeline developments include TECFIDERA (BG-12), an oral MS treatment candidate undergoing regulatory review, and peginterferon beta-1a, another potential MS therapy. The company is also developing long-lasting recombinant Factor VIII and IX for hemophilia and exploring treatments for neurodegenerative diseases.
The company faces significant risks including its substantial dependence on the sales of its three principal products (AVONEX, TYSABRI, and RITUXAN), the potential for increased competition including biosimilars, the risk of adverse safety events impacting product sales, and challenges related to reimbursement from third-party payors. TYSABRI's risk of progressive multifocal leukoencephalopathy (PML) is a specific concern that requires careful management.
Biogen Idec maintains a strong liquidity position with approximately $3.74 billion in cash, cash equivalents, and marketable securities as of December 31, 2012. The company primarily finances its operations through cash flows from operations and expects these resources to be sufficient for its foreseeable needs, including R&D, capital expenditures, and potential strategic initiatives. The company also actively engages in share repurchases.